No profile data available.
SciSparc Ltd. (SPRC) is an essential consumer products company in the marijuana product manufacturing industry, based in Tel Aviv-Yafo, Israel, with about 3 full-time employees.
It reported revenue of $856,000 for fiscal year 2025, down 34.5% from fiscal year 2024, and net income of -$12.18 million. Its market capitalization was $103.14 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.
SciSparc reported $856,000 in revenue for fiscal year 2025, down 34.5% from $1.31 million in fiscal year 2024.
$103.14 million as of October 9, 2026.
Listed companies of a similar size in the same industry (marijuana product manufacturing) include Aurora Cannabis Inc. (ACB), Cresco Labs Inc. (CRLBF), Organigram Global Inc. (OGI), InterCure Ltd. (INCR).